Congenital hyperinsulinism
Tidsskr Nor Laegeforen. 2023 Dec 11;143(18).
doi: 10.4045/tidsskr.23.0425.
Print 2023 Dec 12.
[Article in
English,
Norwegian]
Affiliations
- 1 Klinisk institutt 1, Universitetet i Bergen.
- 2 Seksjon for nyfødte, Barne- og ungdomsklinikken, Haukeland universitetssjukehus.
- 3 Seksjon for gastroenterologi og ernæring, Barne- og ungdomsklinikken, Haukeland universitetssjukehus.
- 4 Seksjon for endokrinologi og metabolisme, Barne- og ungdomsklinikken, Haukeland universitetssjukehus.
- 5 Klinisk institutt 1, Universitetet i Bergen, og, Avdeling for patologi, og, Seksjon for kreftgenomikk, Haukeland universitetssjukehus.
- 6 Klinisk institutt 2, Universitetet i Bergen, og, Barne- og ungdomsklinikken, Haukeland universitetssjukehus.
Abstract
This clinical review will give doctors who work with children and neonates an introduction to the diagnosis and treatment of congenital hyperinsulinism, the most common cause of persistent neonatal hypoglycaemia. The condition is a rare monogenic disorder characterised by elevated insulin secretion and is a result of mutations in genes that regulate insulin secretion from pancreatic beta cells. The anabolic effect of insulin induces systemic glucose uptake and inhibits gluconeogenesis, glycogenolysis, ketogenesis and lipolysis. Low levels of glucose and ketone bodies in the blood are harmful to the central nervous system and can lead to brain damage or death. Early diagnosis and treatment of congenital hyperinsulinism are therefore crucial for a good prognosis.
MeSH terms
-
Child
-
Congenital Hyperinsulinism* / diagnosis
-
Congenital Hyperinsulinism* / drug therapy
-
Congenital Hyperinsulinism* / genetics
-
Humans
-
Infant, Newborn
-
Insulin
-
Ketone Bodies